Skip to content

Clinical Evaluation of Two Daily Disposable Contact Lenses

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01163760
Enrollment
50
Registered
2010-07-16
Start date
2007-09-30
Completion date
2007-09-30
Last updated
2018-06-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Refractive Error

Brief summary

This study seeks to evaluate the clinical performance of two daily disposable contact lenses.

Interventions

DEVICEetafilcon A

daily disposable contact lens

daily disposable contact lens

Sponsors

Singapore Polytechnic University
CollaboratorUNKNOWN
Visioncare Research Ltd.
CollaboratorOTHER
Johnson & Johnson Vision Care, Inc.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
21 Years to 39 Years
Healthy volunteers
No

Inclusion criteria

* Be between 21 and 39 years of age. * Signed Written Informed Consent and Investigator to record this on Case Report Form (CRF) in appropriate space. * Be existing (i.e. successfully worn for 1-month prior to the study) soft contact lens wearers (no extended wear in the last 3 months, but silicone hydrogels in daily wear are allowed). * Require a visual correction in both eyes (monovision allowed but no monofit). * Have a contact lens spherical distance requirement between -1.00D and -6.00D in both eyes. * Astigmatism of 1.00D or less in both eyes. * Be able to wear the lens powers available for this study. * Be correctable to a visual acuity of 20/30 or better in each eye. * Have normal eyes with no evidence of abnormality or disease. For the purposes of this study a normal eye is defined as one having: * No amblyopia. * No evidence of lid abnormality or infection. * No conjunctival abnormality or infection. * No clinically significant slit lamp findings (i.e. edema, staining, scarring, vascularisation, infiltrates or abnormal opacities). * No other active ocular disease.

Exclusion criteria

* Requires concurrent ocular medication. * Any systemic illness which would contraindicate lens wear or the medical treatment of which would affect vision or successful lens wear. * Clinically significant (Grade 3 or 4) corneal edema, corneal vascularisation, corneal staining, tarsal abnormalities, bulbar injection or any other abnormality of the cornea that would contraindicate contact lens wear. * Diabetic. * Infectious disease (e.g., hepatitis, tuberculosis) or an immunosuppressive disease (e.g., HIV). * Extended lens wear in last 3 months. * PMMA or RGP lens wear in the previous 8 weeks. * Has had refractive surgery. Has had eye injury/surgery within 8 weeks immediately prior to enrollment for this study. * Abnormal lacrimal secretions. * Pre-existing ocular irritation that would preclude contact lens fitting. * Keratoconus or other corneal irregularity. * Pregnancy, lactating or planning a pregnancy at the time of enrollment. * Participation in any concurrent clinical trial or in last 60 days.

Design outcomes

Primary

MeasureTime frameDescription
Lens Comfort1-week follow-upLens comfort was evaluated via the subjective question: How comfortable did your eyes feel at the end of the day when wearing the contact lenses you were provided? (excellent/very good=5...very good=3...Poor=0)

Secondary

MeasureTime frameDescription
Comfort Throughout the Whole Day1-week follow-upComfort throughout the day was evaluated via subjective question: Comfort throughout the whole day and is reported as an aggregate of Agree Strongly and Agree Somewhat.

Other

MeasureTime frameDescription
Comfort While Working on Computer1-week-follow-upComfort throughout the day was evaluated via subjective question: Comfort while working on computer and is reported as an aggregate of Agree Strongly and Agree Somewhat.

Countries

Singapore

Participant flow

Recruitment details

There were 50 subjects enrolled in this single site study, located at Singapore University.

Pre-assignment details

There were 50 patients enrolled and randomized, and 50 patients completed the study.

Participants by arm

ArmCount
Overall
Total number of completed participants are included in baseline measurements.
50
Total50

Baseline characteristics

CharacteristicOverall
Age, Continuous25.0 years
STANDARD_DEVIATION 4.8
Sex: Female, Male
Female
31 Participants
Sex: Female, Male
Male
19 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
EG003
affected / at risk
deaths
Total, all-cause mortality
— / —— / —— / —— / —
other
Total, other adverse events
0 / 120 / 130 / 130 / 12
serious
Total, serious adverse events
0 / 120 / 130 / 130 / 12

Outcome results

Primary

Lens Comfort

Lens comfort was evaluated via the subjective question: How comfortable did your eyes feel at the end of the day when wearing the contact lenses you were provided? (excellent/very good=5...very good=3...Poor=0)

Time frame: 1-week follow-up

Population: Subjects analyzed were those who were enrolled, randomized, and completed the study.

ArmMeasureValue (MEAN)Dispersion
Etafilcon ALens Comfort3.08 units on a scaleStandard Deviation 0.98
Ocufilcon DLens Comfort3.00 units on a scaleStandard Deviation 1.15
Secondary

Comfort Throughout the Whole Day

Comfort throughout the day was evaluated via subjective question: Comfort throughout the whole day and is reported as an aggregate of Agree Strongly and Agree Somewhat.

Time frame: 1-week follow-up

Population: Subjects analyzed were those enrolled, randomized, and completed the study.

ArmMeasureValue (NUMBER)
Etafilcon AComfort Throughout the Whole Day39.2 percentage of participants
Ocufilcon DComfort Throughout the Whole Day36.7 percentage of participants
Other Pre-specified

Comfort While Working on Computer

Comfort throughout the day was evaluated via subjective question: Comfort while working on computer and is reported as an aggregate of Agree Strongly and Agree Somewhat.

Time frame: 1-week-follow-up

ArmMeasureValue (NUMBER)
Etafilcon AComfort While Working on Computer47.0 percentage of participants
Ocufilcon DComfort While Working on Computer42.9 percentage of participants

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026